Drug
Buserelin clinical trials
Also written HOE 766 and ICI 123215.
- studies test it
- 5
- open now
- 0
- in phase 3
- 2
- first study started
- 1999
How studies write it
Studies that test it under each name
Name
Brand
Development codes
Combined with it in one product
Studies by the year they started
5 studies that test it; most in 1999 (1)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2009 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 3
- 2
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 5
NRG Oncology (1) · NCIC Clinical Trials Group (1) · Regionshospitalet Viborg, Skive (1) · Institut Paoli-Calmettes (1) · Andros Day Surgery Clinic (1)
Often tested with
Tested in the same studies.
Bicalutamide (2) · Flutamide (2) · Goserelin (2) · Leuprolide (2) · Darolutamide (1) · Degarelix (1) · Histrelin (1) · Relugolix (1)
Studies
Open first, then newest update. How each study uses Buserelin is read from its arms, and is right about nine times in ten.
Testing it · 5
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialActive, not recruitingPhase 3NRG OncologyNCT05050084Written as Buserelin
- Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate CancerCompletedPhase 3NCIC Clinical Trials GroupNCT00003653Written as buserelin
- Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate CancerTerminatedPhase 1Institut Paoli-CalmettesNCT02487823Written as BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide
- Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) CyclesTerminatedPhase 4Andros Day Surgery ClinicNCT01816789Written as buserelin
- Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist CyclesCompletedPhase 4Regionshospitalet Viborg, SkiveNCT00627406Written as Buserelin and Pregnyl
Given in every arm · 5 — Buserelin is usual care beside what is tested
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialActive, not recruitingPhase 3NRG OncologyNCT04513717Written as Buserelin
- Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate CancerTerminatedPhase 3NCIC Clinical Trials GroupNCT00651326Written as buserelin
- Co Administration of GnRH Agonist and hCG for Final Oocyte MaturationCompletedPhase 4Mount Sinai Hospital, CanadaNCT02703584Written as Buseralin
- Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate CancerCompletedPhase 3NCIC Clinical Trials GroupNCT00002633Written as buserelin
- Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using VitrificationStatus unknownPhase 1/2Yazd Research & Clinical Center for InfertilityNCT00823121Written as buserelin
As the comparator · 3 — what is tested is compared with Buserelin
- Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare up Protocol in Poor RespondersCompletedPhase 4Yazd Medical UniversityNCT01213147Written as buserelin
- Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH AgonistCompletedPhase 4Yazd Research & Clinical Center for InfertilityNCT00830492Written as buserelin
- Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRHStatus unknownPhase 3Yazd Research & Clinical Center for InfertilityNCT00823602Written as suprefact
Codes
What other systems call Buserelin · ClinicalTrials.gg INT007100
- MeSH (NLM) D002064BuserelinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) PXW8U3YXDVBUSERELINConfirmed FDA, NLM, Wikidata
- RxNorm 1825Confirmed FDA, Wikidata
- Wikidata Q414745buserelinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C320BuserelinOne source FDA
- DrugBank DB06719One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D002064 | Buserelin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | PXW8U3YXDV | BUSERELIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1825 | — | Confirmed FDA, Wikidata |
| Wikidata | Q414745 | buserelin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C320 | Buserelin | One source FDA |
| DrugBank | DB06719 | — | One source Wikidata |
Also registered as buserelin acetate (UNII 13U86G7YSP · RxNorm 42569).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.